The research team set out to answer a deceptively simple question: when prostate cancer cells stop responding to enzalutamide, what has actually changed inside them? Resistance is often described in terms of genetic mutations in the androgen receptor or amplification of the receptor gene itself, but these alterations explain only a fraction of clinical cases. Increasingly, cancer biologists have recognized that drug-tolerant cells frequently survive by adjusting their metabolism, the network of chemical reactions that converts nutrients into energy, building blocks and signaling molecules. Because metabolic rewiring is a physical requirement for survival rather than an optional accessory, it may represent a more universal and more druggable hallmark of resistance than any single mutation.

To capture that rewiring comprehensively, the investigators applied a multi-omic pipeline to paired models of enzalutamide-sensitive and enzalutamide-resistant prostate cancer cells. Transcriptomic sequencing revealed which genes were switched on or off; proteomic mass spectrometry quantified the enzymes actually present in the cells; and metabolomic profiling measured the small molecules, sugars, amino acids and lipids that flow through the metabolic network. The power of this approach lies in its convergence. A change in a single data type can be misleading, but when altered messenger RNA, altered protein and altered metabolite levels all point to the same pathway, the evidence becomes difficult to dismiss.

The analysis converged on several interconnected metabolic shifts. Resistant cells displayed a marked reorganization of lipid metabolism, upregulating pathways for fatty acid synthesis and elongation while also altering cholesterol handling. This makes biological sense for prostate cancer in particular, because the androgen receptor does more than respond to testosterone; it also regulates genes involved in lipid acquisition and synthesis, and membrane lipid composition influences receptor signaling at the cell surface. By boosting de novo lipogenesis, resistant cells appear to buffer themselves against the loss of androgen-driven lipid programs that enzalutamide imposes, effectively rebuilding a supply line the drug was designed to cut.

Energy metabolism showed equally telling changes. Profiling of central carbon metabolism indicated that resistant cells leaned more heavily on glycolysis and on glutamine-fueled anaplerosis, the process by which the amino acid glutamine tops up the tricarboxylic acid cycle with carbon. Mitochondrial oxidative phosphorylation was also reconfigured, with altered expression of electron transport chain components suggesting a shift in how resistant cells balance ATP production against the generation of biosynthetic precursors. These are not idle adjustments. Rapidly dividing tumor cells must simultaneously produce energy, reduce cellular building blocks and maintain antioxidant defenses, and the observed pattern is characteristic of cells that have traded metabolic efficiency for metabolic flexibility.

Crucially, the study did not stop at description. The researchers tested whether the metabolic alterations they detected could be exploited therapeutically. Inhibiting key enzymes in the upregulated lipid synthesis pathway reduced the viability of enzalutamide-resistant cells more severely than that of their drug-sensitive counterparts, indicating a genuine dependence rather than incidental correlation. Similar experiments targeting glutamine metabolism and mitochondrial respiration produced the same pattern of selective vulnerability. When metabolic inhibitors were combined with continued enzalutamide treatment, the effect was additive, and in some settings synergistic, meaning that the resistant cells could be resensitized to the drug they had learned to ignore.

The concept underlying these results is known as collateral vulnerability. When cancer cells evolve resistance to one pressure, the evolutionary path they take often creates new dependencies that did not exist before. A cell that ramps up fatty acid synthesis to survive androgen receptor blockade, for example, becomes exquisitely sensitive to inhibitors of that synthesis pathway. Because these dependencies are consequences of the resistance program itself, they are less likely to be bypassed by further tumor evolution without a significant fitness cost. This is the same logic that has made synthetic lethal strategies, such as PARP inhibition in DNA repair-deficient tumors, one of the most productive ideas in modern oncology, now extended into the metabolic arena.

The findings carry practical implications for the clinic. Enzalutamide resistance currently marks a transition point at which patients move toward chemotherapy, androgen biosynthesis inhibitors or, for those with suitable tumor biology, radioligand therapy. If metabolic vulnerabilities of the kind identified here can be confirmed in patient-derived models and ultimately in clinical trials, metabolic inhibitors could be layered onto existing regimens at the first sign of rising prostate-specific antigen during enzalutamide treatment, potentially delaying or preventing overt resistance. The study also raises the possibility of using metabolic imaging or circulating metabolite profiles as biomarkers, allowing clinicians to detect the metabolic shift before the tumor has fully escaped hormonal control.

Several caveats temper the enthusiasm. Cell line models, even well-characterized ones, capture only part of the complexity of human tumors, which contain stromal cells, immune infiltrates, variable oxygen and nutrient availability and extensive intratumoral heterogeneity. Metabolic phenotypes are notoriously context-dependent, shaped by the culture conditions in which cells are grown and by the specific evolutionary path each resistant line has taken. The authors’ use of multiple paired models and convergent multi-omic evidence strengthens their conclusions, but translating these dependencies into patients will require validation in organoids, xenografts and ultimately biopsy material from men whose disease has progressed on enzalutamide. Dose-limiting toxicities of metabolic inhibitors, particularly those affecting normal tissues with high metabolic flux, will also need careful management.

Nevertheless, the study represents a meaningful step toward a more complete picture of how prostate cancer defeats one of its most important therapies. By treating metabolism not as background housekeeping but as a central player in drug resistance, and by interrogating that metabolism with layers of molecular data rather than single measurements, the work provides both a mechanistic map and a practical target list. For the growing population of men living with castration-resistant prostate cancer, the hope is that the very adaptations tumors use to survive enzalutamide will become the handles by which the next generation of treatments pulls them back into vulnerability.

Subject of Research: Metabolic rewiring in enzalutamide-resistant prostate cancer identified through integrated transcriptomic, proteomic and metabolomic profiling

Article Title: Multi-omic profiling reveals metabolic vulnerabilities in enzalutamide resistant prostate cancer

Article References: Lee, O., Fidelito, G., Zhao, Q., Liu, B., Choi, H., Taylor, R. A., & Watt, M. J. (2026). Multi-omic profiling reveals metabolic vulnerabilities in enzalutamide resistant prostate cancer. Cell Death Discovery. https://doi.org/10.1038/s41420-026-03332-3

Image Credits: AI Generated

DOI: 10.1038/s41420-026-03332-3

Keywords: prostate cancer, enzalutamide, drug resistance, multi-omics, metabolism, lipid metabolism, glutamine, androgen receptor, oxidative phosphorylation, collateral vulnerability, cancer therapeutics, Cell Death Discovery

Triple-negative breast cancer, or TNBC, accounts for a disproportionate share of breast cancer deaths worldwide. Unlike other breast cancers, TNBC cells lack estrogen receptors, progesterone receptors, and excess HER2 protein, the three molecular targets that drive most modern breast cancer therapies. That absence means patients cannot benefit from hormone therapy or HER2-directed drugs, leaving chemotherapy as the main systemic option. The result is high malignancy, an elevated risk of recurrence and metastasis, and limited therapeutic choices. Against this backdrop, the search for compounds that can eliminate TNBC cells through novel mechanisms has become a pressing priority in oncology research.

The compound at the center of the new study belongs to the Schiff base family, a class of organic molecules formed through a condensation reaction first characterized by Hugo Schiff in 1864. Schiff bases contain an imine functional group, a carbon-nitrogen double bond, and have long been prized in medicinal chemistry for their structural versatility and biological activity. VALD-3 itself is a derivative synthesized from o-vanillin, and it is not entirely new to cancer researchers. Earlier work showed that VALD-3 can induce cell cycle arrest and apoptosis in breast cancer cells by inhibiting the Wnt/β-catenin pathway, and separate studies found it suppresses colorectal cancer cells by upregulating the tumor suppressor p53. The new research, however, uncovers a far more dramatic mode of action.

When the research team, led by Xuhui Zhao of Gansu Provincial Hospital in Lanzhou and including collaborators from Northwest Normal University, exposed breast cancer cells to VALD-3 in the laboratory, they observed cytotoxic effects on both TNBC cells and estrogen receptor-positive MCF-7 cells. Crucially, however, the compound was significantly more potent against the triple-negative cells. And the way those cells died was anything but ordinary. Under the microscope, the cells displayed the unmistakable hallmarks of pyroptosis: they swelled dramatically, sprouted balloon-like protrusions from their membranes, and eventually burst, releasing a flood of inflammatory cytokines into their surroundings.

Pyroptosis is a relatively recent addition to the catalog of programmed cell death. Long familiar as apoptosis, the quiet, orderly suicide of cells, biologists have increasingly recognized that cells can also die in a much louder fashion. First described in immune cells infected by bacteria, pyroptosis is a form of inflammatory programmed cell death in which pores form in the plasma membrane, causing the cell to swell, rupture, and spill its pro-inflammatory contents. The gasdermin family of proteins provides the execution machinery. When a gasdermin protein is cleaved, its pore-forming domain is unleashed, punching holes in the cell membrane. One member of this family, gasdermin E, or GSDME, has attracted particular attention because it can convert the apoptotic program into pyroptosis: caspase-3, the central executioner of apoptosis, can cleave GSDME, transforming a silent death into an explosive one. Intriguingly, GSDME has also been shown to suppress tumor growth by activating anti-tumor immunity, which makes inducing GSDME-dependent pyroptosis an attractive strategy in cancer therapy.

The mechanistic detective work in the new study traced a clear signaling cascade from the initial drug exposure to the final rupture of the cell membrane. The first domino to fall was reactive oxygen species, or ROS. VALD-3 treatment caused ROS levels inside TNBC cells to climb. Far from being mere metabolic noise, ROS at high levels act as potent signaling molecules, particularly within the mitochondria, the energy-producing organelles that are also central arbiters of cell death decisions. Excessive mitochondrial ROS is a well-established trigger of apoptotic signaling, and many anticancer agents exploit precisely this vulnerability.

The rising ROS levels in turn drove the phosphorylation of JNK, a stress-activated protein kinase that relays oxidative stress signals to the mitochondrial machinery. Activated JNK promoted the recruitment of Bax, a pro-apoptotic member of the Bcl-2 protein family, to the outer mitochondrial membrane. There, Bax formed a heterodimer with Bcl-2, the family’s signature anti-apoptotic protein, effectively neutralizing the cell’s principal defense against self-destruction. With Bax entrenched on the mitochondria and Bcl-2 sequestered, the outer mitochondrial membrane became permeable, and cytochrome c, a protein normally tucked away in the space between the mitochondrial membranes, spilled into the cytoplasm. This release is the classic point of no return in the intrinsic apoptotic pathway.

Once in the cytoplasm, cytochrome c set in motion the activation of caspase-3, the protease that dismantles the cell from within. But here the story took its decisive turn. Instead of ending quietly in apoptosis, the activated caspase-3 cleaved gasdermin E. The cleaved GSDME fragments migrated to the plasma membrane and began forming pores, producing the swelling, ballooning, and inflammatory rupture that the researchers had observed. In other words, VALD-3 hijacked the standard apoptotic machinery and diverted it into pyroptosis, initiating the ROS/JNK/Bax-mitochondrial apoptosis pathway and culminating in caspase-3 activation and GSDME cleavage. The result was the complete eradication of the cancer cells through a mechanism that simultaneously recruits the immune system to the tumor site.

Perhaps the most clinically tantalizing observation is the selectivity of this process. Although VALD-3 was toxic to both TNBC and ER-positive MCF-7 cells, the characteristic pyroptotic features emerged selectively in the triple-negative cells. This preferential induction of pyroptosis in the harder-to-treat subtype suggests that TNBC cells may be especially vulnerable to this form of death, or that their GSDME expression and mitochondrial stress responses make them uniquely susceptible to the ROS-driven cascade. Either way, the specificity offers a potential therapeutic window: a treatment that devastates TNBC cells while sparing mechanisms that might fuel inflammation-driven progression in other tumor contexts.

The study is not the first to connect ROS-driven stress to GSDME-dependent pyroptosis in TNBC. Tetraarsenic hexoxide, for example, has been reported to promote pyroptosis in these cells through mitochondrial ROS generation and caspase-3/GSDME activation, and triclabendazole, a veterinary anthelmintic, has been shown to activate the same caspase-3/GSDME axis in breast cancer cells. What distinguishes the new work is both the identity of the agent, a rationally designed Schiff base derivative with a growing portfolio of anticancer activity, and the completeness of the pathway map, which connects ROS production through JNK phosphorylation, Bax mitochondrial recruitment, Bcl-2 sequestration, cytochrome c release, and caspase-3 activation all the way to GSDME cleavage and membrane rupture.

The researchers, based at Gansu Provincial Hospital, The First People’s Hospital of Longxi County, and Northwest Normal University, also tested the compound’s effects on tumor growth in vivo, reporting that VALD-3 treatment inhibited tumor growth, consistent with the pyroptotic cell death observed in culture. The work was funded by the Natural Science Foundation of China and several Gansu provincial research programs, reflecting a concerted effort to develop locally synthesized chemical entities into credible anticancer candidates.

There are, of course, substantial hurdles between a laboratory observation and a clinical therapy. Pyroptosis is a double-edged sword: the inflammatory cytokines released by dying cells can stimulate anti-tumor immunity, but excessive inflammation can also cause tissue damage and, in some contexts, promote tumor progression. Researchers will need to establish careful dosing strategies, verify the selectivity in normal tissues, and determine whether GSDME expression levels in patient tumors can serve as a biomarker to identify who would benefit most from such treatment. The safety profile of VALD-3 in humans remains entirely untested.

Even so, the study adds a compelling entry to the expanding repertoire of pyroptosis-inducing anticancer strategies and offers a new mechanistic explanation for the activity of a compound that researchers have been probing for years. For patients with triple-negative breast cancer, whose options remain constrained by the biology of their disease, the prospect of a small molecule that converts the cancer cell’s own death machinery into an immune-activating fire alarm is a reason for cautious optimism. The findings suggest that GSDME-dependent pyroptosis is a novel mechanism by which VALD-3 eradicates cancer cells, and they offer new insights into potential clinical applications for anticancer therapies aimed at the most aggressive form of breast cancer.

Creating targeted therapies that can selectively block pathways fundamental to tumor growth is critical for advancing oncology. The design of quinoxalinyl and quinolinyl derivatives aims not only at inhibiting ALK5 but also at minimizing off-target effects—a common pitfall in cancer drug development. This presents a fundamental challenge: how to create compounds that are not only effective against the target but also have favorable pharmacological properties. The complexity of the task is underscored by the need for effective synthesis methods that yield compounds in sufficient quantities for further biological evaluation.

The synthesis process detailed in the study is noteworthy, showcasing a multi-step synthetic approach that incorporates various chemical reactions to arrive at the final products. Researchers began their synthetic route by employing established methodologies to generate diverse quinoxalinyl and quinolinyl scaffolds, followed by specific modifications aimed at enhancing the activity and selectivity of these compounds. The precision with which these synthetic alterations were implemented is indicative of an advanced understanding of medicinal chemistry that is essential for success in this field.

Evaluating compound efficacy involves rigorous biological testing. The team conducted in vitro assays to assess the inhibitory activity of the synthesized derivatives on ALK5. These experiments were designed to elucidate the relationship between the structure of the derivatives and their inhibitory potency. Utilizing a dose-response approach allowed researchers to determine how effectively each compound could block ALK5’s kinase activity, providing insight into their potential as therapeutic agents.

In parallel, the study carried out selectivity tests to ensure that these synthesized derivatives did not adversely affect other kinases within the TGF-β signaling pathway. This is vital for confirming the specificity of the compounds, as nephrotoxicity and hepatotoxicity are significant concerns in drug development. Initial results indicate that some derivatives exhibit promising ALK5 inhibitory effects while sparing other kinases, thus validating the initial design strategy.

Moreover, exploring the efficacy of these compounds in cellular models has been a fundamental part of the evaluation process. The application of these quinoxalinyl and quinolinyl derivatives across various cancer cell types offers critical insight into their therapeutic potential. The ability of these compounds to inhibit growth and induce apoptosis in cancer cells is promising, suggesting that they could serve as notable candidates for further development in clinical applications.

A crucial aspect of developing these inhibitors involves investigating their pharmacokinetic properties. Understanding how these compounds are absorbed, distributed, metabolized, and excreted (ADME) is pivotal for assessing their viability as drugs. The study has initiated preliminary assessment regarding the bioavailability and metabolic stability of these quinoxalinyl and quinolinyl derivatives. These factors can significantly impact the potential translation of laboratory successes into clinical settings.

Furthermore, the work emphasizes the importance of collaboration across disciplines. Contributions from biochemists, medicinal chemists, and pharmacologists have culminated in a multifaceted approach, underscoring the interdisciplinary nature of contemporary scientific research. This collaboration is indeed a necessity in the quest to create drugs that are both effective and safe, particularly in treating multifaceted diseases like cancer.

As the research team continues to refine their compounds, they remain committed to elucidating the exact mechanisms by which these quinoxalinyl and quinolinyl derivatives exert their effects on cancer cells. By investigating the downstream signaling cascades affected by ALK5 inhibition, the research could pave the way for identifying novel biomarker signatures that predict patient responses to therapy. This is critical not only for developing personalized treatment regimens but also for advancing the understanding of cancer biology.

The study also highlights the substantial future directions for research once this foundational work has been established. Looking ahead, one potential avenue includes exploring the combination of these inhibitors with existing therapeutics. Such approaches may reveal synergistic effects that enhance overall anticancer efficacy, ultimately providing a broader spectrum of treatment options for patients.

Additionally, advanced drug delivery systems could be designed to improve the bioavailability and targeting of these compounds specifically to tumors. Investigators envision the possibilities of embedding these derivatives in nanoparticles or utilizing cutting-edge methods like CRISPR for enhanced targeting, which could significantly alter the landscape of cancer therapies.

In summary, the pioneering work undertaken by Liu, C., Li, J., and Lu, YQ. marks a vital contribution to the field of molecular diversity and medicinal chemistry. The successful design, synthesis, and biological evaluation of quinoxalinyl and quinolinyl derivatives as ALK5 inhibitors heralds promising new pathways for targeted cancer therapies. This work not only advances the scientific community’s understanding of ALK5 inhibition but also reinforces the necessity for continued innovation and interdisciplinary collaboration in the fight against cancer.

By embracing these scientific advancements, researchers stand at the precipice of new therapeutic horizons that could transform cancer treatment protocols in the coming years. The collective effort observed in this study extends beyond the synthesis of novel compounds; it embodies the global call for curative strategies that cater to the complexities of cancer. With further study and validation, these compounds could potentially evolve into drugs that not only prolong life but enhance the quality of life for individuals battling this formidable disease.

Subject of Research: Inhibition of ALK5 through quinoxalinyl and quinolinyl derivatives as potential cancer therapeutics.

Article Title: Design, synthesis, and biological evaluation of quinoxalinyl and quinolinyl derivatives as ALK5 inhibitors.

Article References: Liu, C., Li, J., Lu, YQ. et al. Design, synthesis, and biological evaluation of quinoxalinyl and quinolinyl derivatives as ALK5 inhibitors. Mol Divers (2026). https://doi.org/10.1007/s11030-025-11444-8

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s11030-025-11444-8

Keywords: ALK5 inhibition, quinoxalinyl derivatives, quinolinyl derivatives, cancer therapeutics, drug design, structure-activity relationship.

At the heart of this experimental therapy is Acoustic Cluster Therapy (ACT), an intricate process leveraging microscopic clusters composed of gas bubbles and oil droplets, collectively known as PS101. This newly conceptualized agent works in conjunction with a modified version of FOLFIRINOX, a robust, FDA-approved chemotherapy regimen comprised of four distinct drugs: leucovorin calcium (folinic acid), fluorouracil, irinotecan hydrochloride, and oxaliplatin. Together, these elements synergize to target and incapacitate malignant cells with unprecedented precision.

The clinical pilot trial underway at HonorHealth Research Institute marks the first global site to administer this combined treatment specifically for pancreatic cancer. The methodology begins with intravenous infusion of PS101, allowing the tiny clusters to circulate and permeate throughout the body, reaching the vicinity of the pancreatic tumor. This step sets the stage for the subsequent ultrasonic intervention that plays a vital role in enhancing the therapeutic effect.

Once PS101 is distributed through the bloodstream, clinicians apply a high-frequency ultrasound directed at the tumor site. The acoustic energy causes the microclusters within PS101 to coalesce into larger bubbles, which temporarily lodge within the capillaries—the smallest blood vessels responsible for gas exchange between oxygen and carbon dioxide. This physical entrapment localizes the drug-laden bubbles precisely where the tumor demands the greatest therapeutic concentration.

Following this initial acoustic seeding, the treatment protocol employs low-frequency ultrasound waves. These sound waves induce oscillations in the lodged ACT bubbles, effectively agitating and destabilizing them. This mechanical action facilitates increased permeability of the tumor’s vasculature and surrounding tissue, vastly improving the penetration and uptake of chemotherapy. As a result, more of the drug reaches the malignant cells while minimizing systemic exposure and collateral damage to healthy tissues.

Dr. Erkut Borazanci, the medical director of the Oncology Research Division at HonorHealth, articulates the significance of this modality: “By enhancing drug delivery directly to the tumor microenvironment without increasing systemic toxicity, we potentially shift the treatment paradigm. Shrinking previously inoperable tumors could open the door for surgical resection, the intervention most correlated with long-term survival.”

The success of this approach relies not only on the innovative engineering of PS101 and the precise application of ultrasound but also on the seamless collaboration across multiple medical disciplines. Interventional radiologists, ultrasound technicians, oncologists, and imaging specialists all bring their expertise to bear during each treatment session. This multidisciplinary teamwork ensures the intricate procedures are carried out with maximal safety and efficacy, benefiting the patients who face formidable challenges due to their diagnosis.

Historically, pancreatic cancer with locally advanced tumors has remained one of the deadliest malignancies, with median survival ranging between 14 and 20 months despite aggressive chemotherapy protocols. Dr. Borazanci remains cautiously optimistic about this trial due to the encouraging precedent established by ACT in treating liver tumors originating from colorectal metastases. These earlier successes provide a proof-of-concept that ACT can potentiate chemotherapy’s impact in deep-seated, difficult-to-access solid tumors.

The pioneering team at HonorHealth, including investigators Erin Pierce, Matt Siegel, Katie Morgan, and S. Danielle Legrand, alongside Dr. Borazanci, will soon share their findings at the highly anticipated “Advances in Pancreatic Cancer Research — Emerging Science Driving Transformative Solutions” conference. This event, hosted by the American Association for Cancer Research (AACR) from September 28 to October 1 in Boston, provides a global platform to disseminate innovative scientific results and catalyze further research collaborations.

Erin Pierce, MSN, APRN, FNP-C and associate clinical investigator leading the study’s abstract, highlights the patient-centered potential of the research: “This method offers a realistic opportunity for patients with borderline or locally advanced pancreatic cancer to qualify for surgery, which significantly improves survival outcomes. The integration of novel therapeutic mechanisms exemplifies our commitment to pushing the boundaries of cancer care.”

In sum, the developments emerging from HonorHealth Research Institute represent a remarkable fusion of biomedical engineering, pharmacology, and clinical oncology. By harnessing the physical dynamics of ultrasound-mediated microbubbles with the pharmaceutical potency of chemotherapeutic agents, this treatment strategy may redefine what is achievable for pancreatic cancer patients worldwide.

Those interested in participating or learning more about ongoing clinical trials at HonorHealth Research Institute are encouraged to contact the research team by calling 833-354-6667 or emailing clinicaltrials@HonorHealth.com. Such innovations hold the promise not only of enhanced treatments but also of transforming pancreatic cancer into a more manageable disease.

HonorHealth Research Institute continues to reaffirm its position as a leader in medical innovation, offering patients access to tomorrow’s transformative therapies today. Situated in Scottsdale, Arizona, this institute draws upon national collaborations to deliver pioneering treatments and elevate patient care standards across multiple disease states.

Subject of Research: People

Article Title: Novel Ultrasound-Enhanced Chemotherapy Shows Promise for Locally Advanced Pancreatic Cancer

News Publication Date: August 16, 2025

Web References: https://www.honorhealth.com/company/research-institute

Keywords: Health and medicine, Clinical medicine